Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/23478193
Conclusion of this study
The results demonstrate a statistically significant and clinically relevant superiority of add-on therapy with EPs 7630 over placebo and a good long-term tolerability in the treatment of moderate to severe COPD. EPs 7630 prolonged time to exacerbations and reduced exacerbation frequency and antibiotic use. Trial Registration No.: ISRCTN01681733.
Supplements analyzed in this study
|
Health conditions analyzed in this study
No health conditions information for this study.Functions related to this study
|
||
|
Body systems related to this study
Respiratory System |